Difference between revisions of "Team:Evry"

(Corrected a bit our first abstract draft, by adding a few things. :))
(Changed title and abstract to something more relevant.)
Line 4: Line 4:
 
     <div class="homepage-header parallax" style="">
 
     <div class="homepage-header parallax" style="">
 
       <div class="header-text">
 
       <div class="header-text">
−
         <h1 class="text-center">Balancing the immune system.</h1>
+
         <h1 class="text-center">Yeast cancer immunotherapy.</h1>
 
         <p class="text-center">EVRY-GENOPOLE IGEM 2015 PROJECT</p>
 
         <p class="text-center">EVRY-GENOPOLE IGEM 2015 PROJECT</p>
 
       </div>
 
       </div>
Line 14: Line 14:
 
     </div>
 
     </div>
 
<h2>Abstract</h2>
 
<h2>Abstract</h2>
−
<p class="lead">Our immune system is a dynamic balance between <strong>immunity</strong> and <strong>tolerance</strong>.</p>
+
<p class="lead">Reshaping immunotherapy landscape.</p>
−
<p class="text-justify" style="font-size: 120%;">This complex mechanism can be impaired, leading to deleterious effects. In <strong>cancer</strong>, the immune system is <strong>tolerant to tumor-associated antigens</strong> that bear homology to self, and is therefore prevented from targeting tumor cells. On the contrary, in <strong>food allergies or inflammatory diseases</strong>, the immune system <strong>overreacts</strong>.</p>
+
<p class="text-justify" style="font-size: 120%;">Cancer thrives by preventing the immune system from targeting tumor cells. While current immunotherapies use dendritic cells to activate T-cells towards specific tumor antigens, they remain expensive and of variable efficiency against tumor immunosuppressive environment. To address these issues, our team mainly focused on engineering a S. cerevisiae yeast immunotherapy that was ultimately tested <strong>in vivo</strong> on mice presenting melanoma.</p>  
−
 
+
<p class="text-justify" style="font-size: 120%;">Three complementary strategies were combined: First, in order to modulate the tumor environment, yeast secreting immune modulators, GM-CSF and IFNgamma, were encapsulated into alginate beads and injected in tumors. Secondly, to break the immune tolerance against cancer cells, T4 and T8 lymphocytes were elicited by a yeast antigen display system. Last, to deliver cytotoxic compounds solely in the tumor environment, a yeast hypoxia bio-sensor was designed. A side project consisted in engineering E. coli to drive MAIT lymphocytes against cancer cells instead of their original targets, parasitized cells.</p>
−
<p class="text-justify" style="font-size: 120%;">Major players of the immune response are <strong>dendritic cells</strong>, that present the antigen to the T cells to ;ature them, leading to an adapted immune response. So we decided to modulate their activity using engineered <em>S. cerevisiae</em> to <strong>rebalance the system</strong>.  Our strategy is to <a href="https://2015.igem.org/Team:Evry/Project/Induction">induce</a> or <a href="https://2015.igem.org/Team:Evry/Project/Repression">repress</a> the immune response through constructions based on known immune modulating molecules which will be expressed at yeast surface and released in the targeted tissues.</p>
+
−
 
+
−
<p class="text-justify" style="font-size: 120%">Thus, in our <strong>induction</strong> project, we are aiming to present <strong>tumor-associated antigens</strong> to dendritic cells, to <strong>break the immune tolerance</strong>, while bringing a favorable immune environment into the tumor with molecules such as cytokines. </p>
+
 
<hr>
 
<hr>
 
<!--p class="lead text-justify">Our immune system can be seen as a balance between immunity and tolerance.  
 
<!--p class="lead text-justify">Our immune system can be seen as a balance between immunity and tolerance.  

Revision as of 17:09, 12 August 2015

Yeast cancer immunotherapy.

EVRY-GENOPOLE IGEM 2015 PROJECT

Welcome!

Abstract

Reshaping immunotherapy landscape.

Cancer thrives by preventing the immune system from targeting tumor cells. While current immunotherapies use dendritic cells to activate T-cells towards specific tumor antigens, they remain expensive and of variable efficiency against tumor immunosuppressive environment. To address these issues, our team mainly focused on engineering a S. cerevisiae yeast immunotherapy that was ultimately tested in vivo on mice presenting melanoma.

Three complementary strategies were combined: First, in order to modulate the tumor environment, yeast secreting immune modulators, GM-CSF and IFNgamma, were encapsulated into alginate beads and injected in tumors. Secondly, to break the immune tolerance against cancer cells, T4 and T8 lymphocytes were elicited by a yeast antigen display system. Last, to deliver cytotoxic compounds solely in the tumor environment, a yeast hypoxia bio-sensor was designed. A side project consisted in engineering E. coli to drive MAIT lymphocytes against cancer cells instead of their original targets, parasitized cells.

Scroll to top To top